Of note is the approval of the intrathecal administration of Nusinersen [8] for the treatment of spinal muscular atrophy (SMA), a disease linked to a homozygous deletion of SMN1 exon 7. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.